Last reviewed · How we verify
Etoricoxib fixed dose
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Etoricoxib fixed dose |
|---|---|
| Also known as | Etori |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the production of pro-inflammatory prostaglandins while sparing the protective effects of COX-1-derived prostaglandins in the gastrointestinal tract and kidneys. This selective mechanism provides anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Ankylosing spondylitis
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Abdominal pain
- Diarrhea
- Headache
Key clinical trials
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (PHASE1)
- Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment (PHASE4)
- Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm (PHASE3)
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis (PHASE3)
- Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis (PHASE3)
- Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain (PHASE3)
- Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil (PHASE3)
- Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etoricoxib fixed dose CI brief — competitive landscape report
- Etoricoxib fixed dose updates RSS · CI watch RSS
- Laboratorios Silanes S.A. de C.V. portfolio CI